

DTIC FILE COPY

SECURITY CLASSIFICATION OF THIS PAGE

AD-A219 870

PORT DOCUMENTATION PAGE

1. REPORT SECURITY CLASSIFICATION Unclassified			1b. RESTRICTIVE MARKINGS										
2. SECURITY CLASSIFICATION AUTHORITY DTIC ELECTE			3. DISTRIBUTION/AVAILABILITY OF REPORT Approved for release; distribution unlimited. (2)										
7b. DECLASSIFICATION/DOWNGRADING SCHEDULE MAR 29 1990			5. MONITORING ORGANIZATION REPORT NUMBER(S) AFOSR TR. 90-0364										
4. PERFORMING ORGANIZATION REPORT NUMBER(S) D			6a. NAME OF PERFORMING ORGANIZATION NOVA Pharmaceutical Corp.										
6b. OFFICE SYMBOL (If applicable)			7a. NAME OF MONITORING ORGANIZATION AFOSR/NL										
6c. ADDRESS (City, State and ZIP Code) 6200 Freeport Centre Baltimore, Maryland 21224			7b. ADDRESS (City, State and ZIP Code) Bolling Air Force Base Washington, D.C. 20032 Bld 410										
8a. NAME OF FUNDING/SPONSORING ORGANIZATION AFOSR			8b. OFFICE SYMBOL (If applicable) NL										
8c. ADDRESS (City, State and ZIP Code) Bolling Air Force Base Washington, D.C. 20332 Bld 410			9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER F-496290-87-C-0071										
11. TITLE (Include Security Classification) Regulation of GABA _A receptors in the rat hippocampus			10. SOURCE OF FUNDING NOS.										
			<table border="1"> <tr> <td>PROGRAM ELEMENT NO.</td> <td>PROJECT NO.</td> <td>TASK NO.</td> <td>WORK UNIT NO.</td> </tr> <tr> <td>61102F</td> <td>2312</td> <td>A.2</td> <td></td> </tr> </table>			PROGRAM ELEMENT NO.	PROJECT NO.	TASK NO.	WORK UNIT NO.	61102F	2312	A.2	
PROGRAM ELEMENT NO.	PROJECT NO.	TASK NO.	WORK UNIT NO.										
61102F	2312	A.2											
12. PERSONAL AUTHOR(S) John Wm. Ferkany, Ph.D., S. J. ENNA													
13a. TYPE OF REPORT Final		13b. TIME COVERED FROM 5/15/87 TO 5/14/90		14. DATE OF REPORT (Yr., Mo., Day) 2/5/90									
15. PAGE COUNT													
16. SUPPLEMENTARY NOTATION													
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)										
FIELD	GROUP	SUB. GR.	GABA, Receptor, cAMP, B-Adrenergic, Receptor Binding Pharmacology										
19. ABSTRACT (Continue on reverse if necessary and identify by block number)													
γ-Aminobutyric acid (GABA) is a key inhibitory neurotransmitter in the mammalian central nervous system. Two major categories of receptors, termed GABA_A and GABA_B, are activated by the amino acid. Whereas GABA_A receptors appear to be directly involved in synaptic transmission, GABA_B receptors may function as neuromodulatory sites. Baclofen (BAC), a GABA_B agonist has been shown to have multiple effects on stimulus-evoked increases in second messenger production. For example, BAC augments cAMP formation in the presence of catecholamines but inhibits the response evoked by the direct adenylate cyclase activator, forskolin. Results from the current study have demonstrated the presence of these GABA_B effects in several mammalian species suggesting a broad physiological relevance. Using a variety of different pharmacophores, evidence is presented supporting the notion that the augmenting and inhibitory efforts of GABA_B.													
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT UNCLASSIFIED/UNLIMITED ☒ SAME AS RPT. ☐ DTIC USERS ☐			21. ABSTRACT SECURITY CLASSIFICATION Unclassified										
22a. NAME OF RESPONSIBLE INDIVIDUAL William C. Barry			22b. TELEPHONE NUMBER (Include Area Code) 1202 747-5621		22c. OFFICE SYMBOL NL								

INSTRUCTIONS FOR PREPARATION OF REPORT DOCUMENTATION PAGE

GENERAL INFORMATION

The accuracy and completeness of all information provided in the DD Form 1473, especially classification and distribution limitation markings, are the responsibility of the authoring or monitoring DoD activity.

Because the data input on this form will be what others will retrieve from DTIC's bibliographic data base or may determine how the document can be accessed by future users, care should be taken to have the form completed by knowledgeable personnel. For better communication and to facilitate more complete and accurate input from the origination of the form to those processing the data, space has been provided for the name, telephone number and office symbol of the DoD person responsible for the input cited on the form. These are to be noted in Block 22.

All information on the DD Form 1473 should be typed.

Only information appearing on or in the report, or applying specifically to the report in hand should be reported. If there is any doubt, the block should be left blank.

Some of the information on the forms (e.g., title, abstract) will be machine-indexed. The terminology used should describe the content of the report or identify it as precisely as possible for future identification and retrieval.

SPECIAL NOTE: UNCLASSIFIED ABSTRACTS AND TITLES DESCRIBING CLASSIFIED DOCUMENTS MAY APPEAR SEPARATELY FROM THE DOCUMENTS IN AN UNCLASSIFIED CONTEXT, E.G., IN DTIC ANNOUNCEMENT BULLETINS AND BIBLIOGRAPHIES OR BY ACCESS IN AN UNCLASSIFIED MODE TO THE RDT/E ON-LINE SYSTEM. THIS MUST BE CONSIDERED IN THE PREPARATION AND MARKING OF UNCLASSIFIED ABSTRACTS AND TITLES.

The Defense Technical Information Center (DTIC) is ready to offer assistance to anyone who needs and requests it. Call Data Base Input Division (AUTOVON) 284-7044; Com 202-274-7044.

SPECIFIC BLOCKS

SECURITY CLASSIFICATION OF THE FORM:

In accordance with DoD 5200.1-R, Information Security Program Regulation, Chapter VI Section 2, paragraph 4-200, classification markings are to be stamped, printed, or written at the tops and bottom of the form in capital letters that are larger than those used in the text of the document. See also DoD 5220.22-M, Industrial Security Manual for Safeguarding Classified Information, Section II, paragraph 11a(2). This form should be nonclassified, if possible.

Block 1.a. Report Security Classification: Designate the highest security classification of the report. (See DoD 5200.00.1-R, Chapters I, IV, VII, XI, Appendix A).

Block 1.b. Enter the restricted marking or warning notice of the report (e.g., CNWDI, RD, NATO).

Block 2.a. Security Classification Authority: Enter the commonly used markings in accordance with DoD 5200.1-R, Chapter IV, Section 4, paragraph 4-400 and 4-402. Indicate classification authority.

Block 2.b. Declassification/Downgrading Schedule: Indicate specific date or event for declassification or the notation "Originating Agency Determination Required" or "OADR." Also insert (when applicable) downgrade to: _____ on _____, (e.g., "Downgrade to Confidential on 6 July 1983"). (See also DoD 5220.22-M, Industrial Security Manual for Safeguarding Classified Information, Appendix II).

NOTE: Entry must be made in Blocks 2.a. and 2.b. except when the original report is unclassified and has never been upgraded.

Block 3. Distribution/Availability Statement of Report: Insert the statement as it appears on the report. If a limited distribution statement is used, the reason must be one of those given by DoD Directive 5200.20, Distribution Statements on Technical Documents. The Distribution Statement should provide for the broadest distribution possible within limits of security and controlling office limitations.

Block 4. Performing Organization Report Number(s): Enter the unique alphanumeric report number(s) assigned by the organization originating or generating the report from its research and whose name appears in Block 6. These numbers should be in accordance with ANSI STD 239.23-74 "American National Standard Technical Report Number." If the Performing Organization is also the Monitoring Agency, enter the report number in Block 4.

Block 5. Monitoring Organization Report Number(s): Enter the unique alphanumeric report number(s) assigned by the Monitoring Agency. This should be a number assigned by a Department of Defense or other government agency and should be in accordance with ANSI STD 239.23-74 "American National Standard Technical Report Number." If the Monitoring Agency is the same as the Performing Organization enter the report number in Block 4 and leave Block 5 blank.

Block 6.a. Performing Organization: For in-house reports, enter the name of the performing activity. For reports prepared under contract or grant, enter the contractor or the grantee who generated the report and identify the appropriate corporate division, school, laboratory, etc., of the author.

Block 6.b. Enter the office symbol of the performing organization.

Block 6.c. Enter the address of the performing organization, list city, state and ZIP code.

Block 7.a. Monitoring Organization - Name: This is the agency responsible for administering or monitoring a project, contract, or grant. If the monitor is also the performing organization, leave Block 7.a. blank. In the case of joint sponsorship, the monitoring organization is determined by advanced agreement. It can be either an office, a group, or a committee representing more than one activity, service or agency.

agonists are mediated through pharmacologically distinct reports. Finally, the augmenting response does not appear to be mediated through protein kinase C. However, BAC may facilitate second messenger production by altering the coupling of catecholamine receptor to G-proteins involved in the cAMP cascade. ~~100~~

CONTRACT NUMBER: F-496290-87-C-0071

REGULATION OF NEUROTRANSMITTER RESPONSES IN THE CENTRAL NERVOUS SYSTEM

John Wm. Ferkany, Ph.D.
Nova Pharmaceutical Corporation
6200 Freeport Centre
Baltimore, Maryland 21224

February 5, 1990

Final Report for the Primary Contractor for the Grant Period 15 May, 1987 - 14 May, 1989

Prepared for:
Nova Pharmaceutical Corporation
6200 Freeport Centre
Baltimore, Maryland 21224

Department of the Air Force
Air Force Office of Scientific Research (AFSC)
Bolling Air Force Base
Washington, DC 20332

Accession For	
NTIS - CR&D	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By	
Distribution	
Availability Codes	
Dist	Availability Codes
A-1	

Regulation of Neurotransmitter Responses in the Central Nervous System

A. Statement of the work.

As outlined in the initial proposal, substantial evidence is available indicating that γ -aminobutyric acid (GABA), acting through GABA_B receptors, modulates second messenger responses to neurotransmitters in mammalian central nervous system tissues. In particular, it is known that activation of GABA_B receptors augments neurotransmitter-stimulated cAMP formation while inhibiting forskolin-mediated nucleotide production. The contract explored this interaction from a pharmacological and mechanistic perspective. The results of the studies further revealed which component of the cyclic nucleotide generating system is influenced by GABA agonists and the mechanism whereby these drugs alter second messenger responses to neurotransmitters or neuroactive agents. The data are important since they may provide new insights into the modulation of synaptic activity and lead to the development of drugs capable of causing subtle alterations in central nervous system function.

B. Status of Research Effort.

1. Year one period.

Details of research accomplishments made during the initial year of the contract are described in the Annual Technical Report (11-11-88; Exhibit A). First, results of these studies provided suggested that the effects of GABA_B agonists on second messenger production were common to several mammalian species. Second, evidence was provided indicating that pharmacologically distinct GABA_B receptors may mediate the inhibitory and augmenting responses of GABA_B agonists on cAMP production. Third, from a mechanistic perspective, the data suggested that neither adenosine nor the ubiquitous protein kinase C was involved in the GABA_B-receptor mediated augmentation of catecholamine-stimulated cAMP production.

The sum of these results were important since they suggested (1) the interaction of GABA_B agonists with neurotransmitter systems was of general physiological relevance to mammalian central nervous system function and (2) that multiple GABA_B receptors may exist in the brain. Although the mechanistic data was negative, by eliminating the involvement of at least one pathway, they served to focus the search for those processes and pathways involved in the observed events.

2. Year two period.

2a. Mechanism. During the second year of the contract, efforts continued to focus on defining the mechanism by which activation of GABA_B receptors influenced cAMP production. Important findings are described in detail in Exhibit B.

Briefly, results of these investigations demonstrated that exposure of brain slices to GABA_B agonists in vitro altered the distribution and affinity of β -adrenergic receptors in membrane homogenates made from these tissue preparations. In particular, pre-incubation of rat cortical slices in the presence of baclofen (BAC) increased the potency of isoproterenol to inhibit [¹²⁵I]idopindolol binding to high and low affinity β -adrenergic receptors. Additionally, the BAC pre-exposure altered the distribution of high and low affinity receptors, significantly increasing the proportion of receptors in the low affinity state. The effect of BAC was stereospecific, and with the pharmacologically important L-isomer being the active component. At low (1 μ M) concentrations of L-BAC, the predominant effect was an alteration of receptor distribution; higher (10 μ M) amounts of the drug induced shifts in both receptor distribution and receptor affinity.

The endogenous neurotransmitter, GABA (25 μ M), mimicked the actions of BAC. Indeed, the influence of GABA was more pronounced than L-BAC and pre-exposure to the amino acid appeared to convert β -adrenergic receptors to a homogeneous population of sites having an intermediate affinity for isoproterenol. Importantly, the action of GABA was not reduced by the specific GABA_A antagonist, bicuculline, nor did the GABA_A agonist, isoguavacine, mimic the actions of BAC. Finally, the effect of GABA_B receptor activation on β -adrenergic receptors may be of physiological relevance since an intact tissue preparation was required.

The data were interpreted to suggest that GABA_B receptor activation modified the coupling between β -adrenergic receptors and guanine nucleotide-binding proteins, and that this modification may, in part, explain the ability of BAC to augment catecholamine-stimulated cAMP accumulation in brain slices.

2b. Pharmacology. Additional studies explored the pharmacological profile of the GABA_B receptor(s) mediating the augmenting and inhibitory effect of BAC on second messenger production. For example, during the first period of the award, data showed that 3-aminopropane phosphonic acid (3-APPA), a compound lacking agonist or antagonist properties on catecholamine-stimulated cAMP production, was a moderately potent, BAC-like agonist in the presence of forskolin.

Specifically, during the second period, the effects of the putative GABA_B antagonists 3-hydroxy-saclofen (SAC), 2-butyl GABA and 2-decyl GABA on catecholamine- and forskolin-stimulated cAMP production were examined. Of note, whereas 2-butyl GABA lacked either agonist or antagonist properties and SAC appeared to be a GABA_B antagonist in both systems, 2-decyl GABA preferentially antagonized the augmenting effect of BAC on isoproterenol-stimulated second messenger production. These findings, coupled with the differential effects of 3-APPA on GABA_B receptor-mediated effects, lend support to the notion of the multiplicity of GABA_B receptors in brain. Full details of these findings are shown in Exhibit B.

In ancillary studies performed in collaboration with other Nova scientists, but not directly supported by the contract, the effects of GABA_B agonists and antagonists on pulmonary function in vitro was examined. Details of the methods and findings are noted in Exhibit C. Importantly, however, 3-APPA appeared to have GABA_B receptor antagonist properties on tracheal strips, whereas 2-decyl GABA was without effect. Thus, the GABA_B receptor mediating

tracheal strip relaxation may be more similar to central nervous system receptor inhibiting forskolin-stimulated cAMP production.

In sum, these data have been interpreted to support the notion of pharmacologically distinct GABA_B receptors in mammalian tissues. Furthermore, the results predict it may be possible to develop more potent compounds which would discriminate between receptor subtypes thus, subtly modifying synaptic neurotransmitter activity.

2c. Current status. Direct work on the project was terminated at the end of the contract period. An application for additional funding from sources other than AFSC is pending. Further work will be contingent on receipt of such funding.

C. Chronological List of Written Publications.

Scherer, R.W., Karbon, E.W., Ferkany, J.W. and Enna, S.J.: Comparison of baclofen and phorbol esters as augmenters of isoproterenol-stimulated cAMP production in rat brain slices. Soc. Neurosci. Abstracts, 13:1653, 1987 (abs.).

Scherer, R.W., Karbon, E., Ferkany, J.W. and Enna, S.J.: Augmentation of neurotransmitter receptor-stimulated cyclic AMP accumulation in rat brain: differentiation between the effects of baclofen and phorbol esters. Brain Res., 451:361 - 365, 1988.

Scherer, R.W., Ferkany, J.W. and Enna, S.J.: Species-dependent augmentation of receptor-mediated cAMP production by baclofen. Soc. Neurosci. Abs. 14:113, 1988 (abs.).

Scherer, R., Ferkany, J.W., Karbon, E.W. and Enna, S.J.: GABA_B receptor activation modifies beta-adrenergic receptor agonist binding in rat brain cerebral cortex. J. Neurochem., 53:989 - 991, 1989.

Scherer, R.W., Ferkany, J.W. and Enna, S.J.: Evidence for pharmacologically distinct subsets of GABA_B receptors. Brain Res. Bull., 21:429 - 443, 1989.

Karbon, E.W. Zorn, S.H., Newland, R.J. and Enna, S.J.: Pharmacological and biochemical evidence for the existence of multiple GABA_B receptor subpopulations in the central nervous system. First International GABA_B Receptor Symposium, (in press).

D. Key Personnel.

R.W. Scherer, Ph.D., postdoctoral fellow, Nova Pharmaceutical, 1987 - 1989. Direct responsibility for bench research effort.

J. W. Ferkany, Ph.D., Group Leader, CNS Research, Nova Pharmaceutical, 1984 - present. Oversight of laboratory research.

E.W. Karbon, Ph.D., Research Associate, CNS Research, Nova Pharmaceutical, 1989 - present. Oversight of daily research.

S.J. Enna, Ph.D. Senior Vice President for Scientific Affairs, Nova Pharmaceutical, 1987 - present. Project co-ordination and scientific direction.

E. Coupling Activities.

S.J. Enna, Ph.D., invited speaker, First International GABA_B Receptor Symposium, Cambridge, UK, September 17 - 20, 1989.

REPORT OF THE SUBCONTRACTOR

FINAL PROGRESS REPORT

I. Objectives of Research: (1988-89)

- A. To investigate the interactions between brain cyclic nucleotide systems and β -adrenergic, adenosine, and GABA_B receptors.
- B. To compare the effects of a variety of selective cyclic nucleotide phosphodiesterase inhibitors for their ability to alter cyclic nucleotide metabolism and/or turnover in brain. These include Rolipram, a centrally active drug that may selectively inhibit brain cyclic nucleotide phosphodiesterase, and Indolidan, a cardiotonic agent that inhibits a cardiac cyclic nucleotide phosphodiesterase associated with the sarcoplasmic reticulum.
- C. The development of a cell culture system to probe the interactions between these neurotransmitter systems and specific cyclic nucleotide phosphodiesterase isozymes.

II. General Methodological Approaches:

- A. Determine the mechanisms by which pharmacological agents that interact with specific receptors affect the turnover rates of cyclic AMP metabolism in isolated brain slices and cultured PC-12 cells. Adenine-prelabeling is used to label endogenous ATP stores to steady-state levels. Chromatographic methods are used to isolate the amount of cAMP accumulated in the tissue in response to various agonists.
- B. Assay of enzyme activities in cell-free preparations, subcellular fractions, and correlate inhibition of drug effects in vitro with their effects in intact brain slice (ex vivo) or cultured cell preparations.
- C. Isolation, purification and characterization of specific isozymes of brain cyclic nucleotide phosphodiesterases as an approach to develop more specific probes for examining possible effects of drugs on the cyclic nucleotide phosphodiesterase in brain. The development of specific antibodies to one or more of these isozymes; the use of immunocytochemical methods to localize and/or co-localize the isozymes with receptor populations; and the synthesis of photoaffinity probes and affinity ligands for use in the localization and/or purification of these enzyme systems.

III. Personnel:

- A. Dr. Samuel J. Strada devoted ca. 25% of his research effort towards this project, and was compensated at 10% of his salary level.
- B. Dr. Robert Garrett, a postdoctoral fellow devoted ca. 80% of his time toward this research project until July 15, 1988. Dr. Garrett then accepted a position as Assistant Professor of Pharmacology at Campbell University.

- C. Dr. C-C. Shen spent ca. 80% of his research time (July 15, 1988 - May, 1989) on this project following the departure of Dr. Garrett. Dr. Shen is a research associate in our cyclic nucleotide research laboratories and was familiar with the techniques needed for this project.
- D. Mr. Michael Whalin, a graduate student in the Department of Pharmacology devoted a significant portion of his research efforts towards this project in partial fulfillment for his Ph.D. degree in Pharmacology. Mr. Whalin received a stipend from other sources and was not compensated by the grant. Mr. Whalin received his Ph.D. degree and accepted a postdoctoral position at the Georgetown-Fidia Institute for Neurosciences in Washington, D.C.

IV. Significant Findings:

- A. The role of cyclic nucleotide phosphodiesterase isozymes in regulating intracellular cAMP levels was studied using rat brain cortical slices as a model system. The rate of cAMP decay in the absence and presence of selective cyclic nucleotide phosphodiesterase inhibitors after stimulation with adenosine or beta-adrenergic receptor agonists was determined using an adenine prelabeling technique.

The studies show that a rolipram-sensitive, high affinity cAMP phosphodiesterase is primarily responsible for cAMP decay in intact cortical slices following elevation of cyclic AMP levels by either adenosine or beta-adrenergic receptor agonists. Interestingly, this isozyme, which is sensitive to inhibition by the drugs rolipram, RO-20-1724 and SQ-65442 contributes only a small percentage of the total cAMP hydrolytic activity measured in cell-free preparations of cortex. This study provides a good example of how data obtained in cell-free preparations do not always reflect effects observed in intact tissue.

A thorough description of these results is provided in an accompanying reprint (Second Messengers and Phosphoproteins 12:311-325, 1989).

- B. PC 12 cells were studied as a different model system to explore interactions between receptor systems and/or cyclic nucleotides because: 1) the cells were shown to contain only one isozyme of cyclic nucleotide phosphodiesterase, namely, a Type II (cGMP-activatable) form of cyclic nucleotide phosphodiesterase with 50% of the total activity associated with the particulate fraction; 2) they represent a well-characterized population of rat adrenal medullary pheochromocytoma cells having the same embryonic lineage as brain; 3) the cells in culture respond to nerve growth factor by differentiating from chromaffin-like cells to cells that exhibit a neuronal phenotype; 4) the cell line is well-established and can be maintained in culture yielding large quantities of material for experimentation; 5) cyclic nucleotides have been reported to modulate cellular responses in PC 12 cells, eg. neurotransmitter release; 6) the cells contain functional adenosine receptors that

are capable of increasing intracellular cAMP levels, and functional atrial peptide (ANF) receptors that lead to increases in intracellular levels of cGMP, and 7) since no cGMP-dependent protein kinase was detected in these cells, functional effects of cGMP may be attributed to interactions with cyclic nucleotide phosphodiesterase rather than cGMP-dependent protein kinase.

cAMP accumulation induced by adenosine in intact cells showed a dose-dependent rise in cAMP levels with peak responses (5-8 fold) at 5 min; removal of adenosine by the addition of adenosine deaminase resulted in the rapid decay of cAMP to basal levels in 3 min. The drugs Papaverine or Trequensin (HL-725), which inhibit the Type II PDE activity in vitro, potentiate adenosine responses, whereas preincubation of PC 12 cells with nitroprusside or the atrial peptide (which increase cGMP levels in these cells), attenuate adenosine-induced cAMP accumulation and increase the rate of decay of cAMP.

We conclude from these studies that increases in cGMP levels regulate cAMP metabolism via the activation of a Type II PDE. These results may have significant implication for the general regulation of synaptic transmission via a dual control mechanism involving both cAMP and cGMP.

A more thorough description of these results is provided in abstract and pre-print accompanying this report.

- C. We developed a monoclonal antibody to a Type II isozyme. The antibody was generated against a protein purified from rabbit brain, which had physico-chemical and pharmacological properties very similar to the isozyme identified in PC 12 cells. However, the antibody failed to immunoreact with the enzyme from rat brain or cultured rat PC-12 cells. The antibody, however, did immunoprecipitate activity in rabbit brain extracts and a protein of ca. 110 kD was detected by Western blot analysis. With hindsight, it now seems clear that the development of a polyclonal antibody to the isozyme of interest would have been a more prudent experimental approach.

A comprehensive description of our progress in purifying a membrane-associated enzyme from rabbit brain and the development of specific probes to study this isozyme in brain has been published (Biochim. Biophys. Acta 972:79-94, 1988).

Contract F496290-87-C-0071
Annual Technical Report

Exhibit B

Objectives of Research: (1987-88)

- 1) To examine the role of specific isozymes of cyclic nucleotide phosphodiesterase in regulating cyclic nucleotide metabolism in brain.
- 2) To explore the interactions between various mediators of synaptic transmission using the cyclic nucleotide system as a probe.
- 3) To investigate the interactions between beta-adrenergic receptors, adenosine receptors, and peptidergic receptors and the GABA_B system of brain.
- 4) To determine whether the ability of Baclofen and other GABA_B agonists to potentiate the effects of isoproterenol, norepinephrine and adenosine in elevating cyclic AMP levels in the brain are attributable to specific effects on selective isozymes of cyclic nucleotide phosphodiesterase in brain.
- 5) To study the actions of rolipram, a relative specific inhibitor of Type IV cyclic nucleotide phosphodiesterase in the brain as compared to the effects of Baclofen.

General Methodological Approaches:

- 1) Isolate discrete nuclei of brain by punch techniques.
- 2) Determine activities of cyclic nucleotide phosphodiesterase in these nuclei and in subcellular fractions of brain tissue using methodologies developed to measure selective isoenzymes.
- 3) Determine the effects of baclofen and other pharmacological agents on the turnover rate of cyclic nucleotide metabolism in isolated brain slices using labeled-adenosine to label endogenous ATP pools and chromatographic methods to isolate the amount of cyclic AMP accumulated in the tissue in response to various pharmacological agents.
- 4) Correlations of enzyme activities measured in broken-cell preparations with their effects on the ex vivo brain slice preparation.

Personnell:

- 1) Dr. Samuel J. Strada devoted 10% of his research efforts toward this project
- 2) Dr. Robert Garrett, Jr., Postdoctoral Fellow, devoted ca. 80% of his research effort toward this project.
- 3) at various times, Mr. Michael Whalin or Mr. Philip Kithas, graduate students in the Department of Pharmacology worked on various aspect of the study.

Future Directions (1988-89).

- 1) To continue to explore the mechanism by which GABA_B agonists potentiate the effects of agents that elevate cyclic AMP accumulation in brain with respect to a) the role of guanine nucleotide binding proteins, b) phosphorylation of baclofen-sensitive proteins, c) cyclic nucleotide phosphodiesterase isozymes.
- 2) To develop more specific probes to examine the possible effects of drugs on the cyclic nucleotide phosphodiesterase enzyme system in brain in intact tissue. This will include a) development of specific antibodies to each of the isozymes of phosphodiesterase; b) development of immunocytochemical techniques to localize these enzymes to specific neuronal and glial cell populations, and subcellular organelles; c) the development of photoaffinity probes to enable the localization of the enzyme, and its potential covalent alteration in response to pharmacological stimuli.

REGIONAL VARIATION OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOENZYMES IN DISCRETE BRAIN NUCLEI.

Previous studies have shown considerable variations in cyclic AMP and cyclic GMP phosphodiesterase (PDE) hydrolytic activities among different brain regions (Soc. Neurosci. 4:386, 1974). To further extend these observations, we analyzed the activities of three distinct types of (PDE) isoenzymes in homogenates of eight brain regions, including four distinct nuclei in which PDE activity had not previously been investigated. The eight areas include cerebellum (CB), dorsal raphe (DR), hippocampus (HC), locus coeruleus (LC), neocortex (FC), neostriatum (NS), substantia nigra (SN), and ventral tegmentum (VT).

Acutely, opiate treatment has been found to inhibit adenylate cyclase resulting in decreased cAMP levels in neostriatum and cerebral cortex (Tsang et al., Brain Res. 152:521-527, 1978; Law et al., J. Neurochem. 36:1834-1846, 1981). Chronic opiate exposure results in a return of cAMP to control levels, with abrupt withdrawal of opiates associated with cAMP increasing above control levels (Sharma et al., Proc. Natl. Acad. Sci., USA 72:590-594, 1975; Traber et al., Life Sci. 16:1863-1868, 1975; Law et al.). The present study examined not only the brain regional variation and distribution of different types of PDE isozymes, but also examined the same brain areas in rats chronically treated with morphine to ascertain whether development of morphine tolerance was associated with any changes in PDE activity levels.

METHODS:

Male, 150-200 g., Sprague-Dawley rats were killed by decapitation, and the brains rapidly removed into ice-cold, oxygenated, physiological saline, for further dissection. The discrete nuclei were excised as 1mm punches from 0.5 to 0.75 mm thick coronal brain sections. All samples were frozen in liquid nitrogen and kept at -70°C until analysis.

The morphine treated animals were implanted subcutaneously with one morphine pellet (containing 75 mg morphine base) a day for five days. This regimen of chronic morphine treatment has been shown to produce a profound state of tolerance and dependence in rats (J. Blasig et al., Psychopharmacologia 33:19-26, 1973). Control rats underwent identical halothane anesthesia and surgery, but without pellet implantation.

The phosphodiesterase assays were performed using the two step procedure of Thompson et al. (Cyclic Nucl. Res. 10: 62-69). The tissues were homogenized in ice cold buffer containing 20 mM Tris-HCl, pH 7.4, 5 mM MgCl₂, 5 mM 2-mercaptoethanol, 250 mM sucrose, 20 uM TLCK, 3 mM PMSF, 20 mM benzamide, and 0.5ug/ml aprotinin. Basal type I activity was assayed using 25 uM cGMP substrate, in the presence of 0.2 mM EGTA. The calmodulin-stimulated activity was assayed with 0.4 mM Ca⁺⁺ and 30 nM calmodulin was purified to homogeneity from bovine brain according to Gopalakrishna and Anderson (Bioc. Biophys. Res. 104:830-836). Cyclic AMP hydrolysis by Type II (cGMP-stimulated) PDE is characteristically enhanced by low levels of cGMP. Type II PDE activity was assayed at 5 uM cAMP substrate in the absence and presence of 2 uM cGMP. The stimulated activity (minus basal) represents the Type II activity present in the sample. Type IV PDE is cAMP-preferring and is often referred to as "high-affinity" or "low-K_m" PDE. The Type IV PDE activity was assayed at 0.25 uM cAMP, in the absence and presence of Rolipram, a specific Type IV PDE inhibitor. The Rolipram-inhibitable activity was considered to represent the Type IV activity present. Protein concentrations were determined using the Bradford dye-binding assay (Analyt. Biochem. 72:248-254), and all PDE activities were expressed as specific activities (nmol/min/mg).

RESULTS:

The SN showed the highest specific activity for all three types of PDE. The LC, DR, VT, and CB displayed very low levels of Types I and II PDE activity compared to the other regions. The Type IV activity was lowest in HP and FC. No differences were seen between control and morphine dependant rats.

Subcellular fractionation revealed Type I PDE to be mostly cytosolic in all brain regions assayed, and Type II to be predominantly membrane-associated, although about evenly distributed in HP. The Type IV PDE subcellular distribution showed the most variation, being mostly particulate in SN and NS, mainly associated with the soluble fraction in LC and DR, and equally distributed in HP and FC.






Figure 1.

(a). Basal PDE activity was assayed using 25 μ M cGMP as substrate in the presence of 0.2 μ M EDTA. The calmodulin-stimulated activity was assayed with 0.4 μ M Ca^{++} and 30 nM calmodulin. The stimulated activity (minus basal) represents the Type I PDE activity present as shown here for brain homogenates.

(b). The subcellular distribution of Type I PDE activity was elucidated following 30,000 $\times$ g centrifugation of homogenate.

(c). The cytosolic and particulate distribution of Type I PDE expressed as a percent of total activity.






Figure 2.

(a). Type II PDE activity was elucidated in brain homogenates by subtracting 'basal' activity, measured at 5 μ M cAMP substrate, from 'stimulated' activity induced by the additional presence of 2 μ M cGMP.

(b). The cytosolic and particulate distribution following 30,000 $\times$ g centrifugation of homogenates.

(c). The subcellular distribution of Type II PDE activity expressed as a percent of total activity.

TYPE IV PDE






Figure 3.

- (a). Type IV PDE activity was assayed at 0.25 μM cAMP substrate.
- (b). Type IV activity assayed in the presence and absence of 100 μM Rolipram, a specific Type IV inhibitor.
- (c). Subcellular distribution of Rolipram-inhibitable PDE activity.

EFFECTS OF SELECTED PHOSPHODIESTERASE (PDE) INHIBITORS ON CALCIUM-DEPENDENT PDE ACTIVITY AND ROLIPRAM BINDING SITES OF CEREBRAL CORTEX. L. L. Buzze, L. A. Labe, and R. E. Keane. Central Research Division, Pfizer Inc., Green, CT 06358.

Rolipram, Ro 26-1724 and ICI 63197 are selective PDE inhibitors that are markedly more active on the calcium-independent (cyclic AMP) enzyme (IPDE) than on the calcium-dependent (cyclic GMP) enzyme (DPDE). Recently, membranes, as well as soluble extracts, of various rat brain regions have been reported to contain stereospecific, high affinity binding sites for [3H]rolipram. These binding sites display a linear Scatchard plot and apparently consist of several types characterized by very rapid, moderately fast or very slow dissociation of the radioligand (Schneider et al., Eur. J. Pharmacol. 127: 105, 1986). In the present study, we confirmed the presence of high affinity binding sites for [3H]rolipram in mouse and rat brain preparations and detected these binding sites in several regions of mouse brain. In addition, we found that the IPDE of rat cerebral cortex (Craig, Biochem. Biophys. Acta 797: 254, 1984) contains high affinity binding sites for [3H]rolipram. Another selective PDE inhibitor, intraziquone (TVX 2706; Glaser and Trauer, Agents Action 15: 341, 1984), was found also to inhibit [3H]rolipram binding. High affinity binding to mouse brain preparations and IPDE was found for [3H]intraziquone, which appears to label the same binding sites as [3H]rolipram. A 2-min association of mouse cortical membranes with either radioligand resulted in binding that was only slowly dissociated by 10 μ M rolipram (22 hr).

Since rolipram is a potent inhibitor of IPDE, it was of interest to ascertain if inhibition of IPDE activity correlated with inhibition of binding to rolipram binding sites. For this purpose, we compared the effects of selected PDE inhibitors on hydrolysis of cyclic AMP by rat cerebral IPDE and [3H]rolipram (and [3H]intraziquone) binding to membranes of mouse cerebral cortex. The rank order of inhibitory potency (IC_{50} in nM) on [3H]rolipram or [3H]intraziquone binding did not parallel the rank order of inhibitory potency on IPDE (IC_{50} in μ M) (Table). These results suggest that inhibition of IPDE may be independent of binding to rolipram binding sites.

Compound	IPDE IC_{50} μ M	[3H]Rolipram IC_{50} nM	[3H]Intraziquone IC_{50} nM
Rolipram	0.40	2.5	4.5
(-)-Rolipram	0.39	1.5	2.6
GVR113780	0.57	15	35
Intraziquone	1.9	15	15
(+)-Rolipram	2.2	5.0	15
Papaverine	4.3	>10000(42%)	>10000(25%)
Proquazone	4.4	7200	10000
Ro 26-1724	6.0	23	30
ICI 63197	6.5	60	100
IBMX	27	700	1300

REGIONAL VARIATION OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOENZYMES IN DISCRETE BRAIN NUCLEI. R. L. Carter, Jr., W. J. Thompson and S. J. Strada. University of South Alabama, Department of Pharmacology, College of Medicine, Mobile, AL 36688, and R. S. Duman, E. J. Nestler, and J. F. Tallman, Yale University, Department of Psychiatry, New Haven, CT 06508.

Previous studies have shown considerable variations in cyclic AMP and cyclic GMP phosphodiesterase (PDE) hydrolytic activities among different brain regions (Sec. Neurosci. 5: 384, 1976). To further extend these observations, we analyzed the activities of three distinct types of (PDE) isoenzymes in homogenates of eight brain regions, including five distinct nuclei. These areas included cerebellum (CB), dorsal raphe (DR), hippocampus (HC), locus coeruleus (LC), neocortex (NC), neostriatum (NS), substantia nigra (SN), and ventral tegmentum (VT). Discrete nuclei were excised as 1mm punches from coronal brain sections prepared from 150 g, male, Sprague-Dawley rats. Samples were homogenized with buffer conditions designed to minimize proteolysis (Adv. Cyclic Nucleotide Res. 10: 69-92, 1979).

SN showed the highest Type I cGMP hydrolytic activity (specific activity; 82 nmol/min/mg), measured at 25 μ M cGMP, and Type IV (high affinity) cAMP PDE activity (8.3 nmol/min/mg), assayed at 0.25 μ M substrate. These activities were 10-20 fold higher in SN than those measured in either DR or LC. The ratio of cGMP to cAMP hydrolytic activity (G/A ratio) was highest in HP and NC and lowest in SN and NS. Type II (cGMP stimulated) PDE activity, assayed at 5 μ M cAMP in the absence and presence of 2 μ M cGMP, showed the greatest cGMP stimulation of cAMP hydrolysis in VT and HP (3.3-3.6 fold), and the least in SN and CB (1.0 fold). Consistent with earlier results, the CB contained the lowest specific activities for each form of PDE. The variations in PDE isoenzyme profiles may have important implications with respect to functional differences in cyclic nucleotide mechanisms among discrete brain nuclei. These studies were supported by a grant from the USPHS (GM 33338) and a contract from the United States Air Force (69620-83-K-0014).

BIOGENIC AMINES: TOXINS

HISTOCHEMICAL LOCALIZATION OF MPTP OXIDATION BY MAO-B IN SEROTONIN AND HISTAMINE NEURONS IN THE MOUSE BRAIN. S.R. Vincent, Division of Neurological Sciences, Department of Psychiatry, University of British Columbia, Vancouver, B.C., V6T 1W5, Canada.

Conversion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to 1-methyl-4-phenylpyridinium (MPP+) appears to be a necessary step for the neurotoxic actions of this drug on the nigrostriatal dopamine system. This conversion is mediated by monoamine oxidase (MAO) of the B type. In the present study, MPTP has been used as a substrate for the histochemical localization of MAO activity in the brain of C57 black mice. The localization of MPTP oxidation by MAO in the brain was compared with the distribution of various monoaminergic neurons determined using immunohistochemistry.

Adult male C57 black mice were anesthetized and perfused with buffered aldehyde fixative. MAO activity was demonstrated on 50 μ m thick vibratome sections by incubating the sections in 50 mM Tris-Cl buffer (pH 8.5) containing 0.9% MPTP hydrochloride, 0.1% horseradish peroxidase, 0.005% diaminobenzidine, 0.6% nickel ammonium sulfate and 0.9% sodium ascorbate. Sections incubated without MPTP showed no positive reaction. For the immunohistochemical localization of catecholamine neurons sections were incubated with antisera against tyrosine hydroxylase, dopamine- β -hydroxylase and phenylethanolamine-N-methyltransferase. Serotonin and histamine neurons were localized with antibodies to cerulein and histidine decarboxylase.

The distributions of monoamine cell groups observed in the mouse brain were similar to those found in the rat. Tyrosine hydroxylase immunohistochemistry demonstrated that the major dopaminergic cell group in the mouse was in the substantia nigra pars compacta and adjacent ventral tegmental area. These dopamine neurons did not display MAO activity when MPTP was employed as a substrate. Instead, MAO activity capable of oxidizing MPTP was found in other discrete groups of neurons. These included the serotonin and noradrenergic neurons of the brainstem, and the histamine neurons of the caudal hypothalamus. Preliminary studies with the MAO-A inhibitor clorgyline blocked the MAO staining in noradrenergic neurons, but not in the serotonin or histamine neurons. The activity in these cell groups was inhibited by the MAO-B inhibitor deprenyl.

These results indicate that MPTP can be converted to the Parkinsonism-inducing toxin MPP+ by MAO-B in serotonin and histamine neurons which innervate the striatum and substantia nigra.

Supported by the British Columbia Health Care Research Foundation.

MPTP EFFECTS ARE REGIONALLY SPECIFIC IN MICE - A NEUROCHEMICAL STUDY. M. Gupta, S.Y. Fekken and D.L. Fekken. Department of Neurobiology and Anatomy, University of Rochester School of Medicine, Rochester, NY 14642.

MPTP causes degeneration of the nigrostriatal dopamine system in humans, non-human primates, and rodents. Although degeneration of the nigrostriatal dopaminergic neurons is the most prominent abnormality in human Parkinsonism, additional monoamine cell groups also are known to be affected by this disease. We previously have shown that MPTP treatment in young adult mice also leads to decreased dopamine levels in the nucleus accumbens and olfactory tubercle (dopamine terminal projection sites from neurons of the ventral tegmental area) in a dose-dependent manner, in addition to decreased dopamine levels in the caudate-putamen (Gupta et al., in: MPTP-A neurotoxin producing a Parkinsonian syndrome, eds. Markey et al., 1985). In the present study, we investigated whether MPTP treatment in mice produces changes in other monoamines in addition to its already established changes in dopamine levels. Young adult male Swiss-Webster mice were injected intraperitoneally with 3, 30, or 60mg MPTP/kg body weight. Control animals received vehicle injections. Treated and control animals were sacrificed by decapitation 21 days following the last injection. Brains were removed quickly and samples from various regions of the brain, both sides and terminal stem, were microdissected, placed in 100mM perchloric acid, frozen and stored in liquid nitrogen. Levels of monoamines were determined using high performance liquid chromatography with electrochemical detection. MPTP treatment increases norepinephrine (NE) levels in the ventral tegmental area and decreases NE levels in substantia nigra, whereas no changes were seen in locus coeruleus, medial basal hypothalamus, dorsal raphe, medullary raphe, and nucleus tractus solitarius. Furthermore, serotonin levels appeared to be decreased in substantia nigra in a dose-dependent manner, but remained unaltered in dorsal raphe, medullary raphe, medial basal hypothalamus, and nucleus tractus solitarius. We conclude that MPTP affects only specific monoaminergic regions of the brain while leaving other regions unaltered.

Supported by USPHS grants RO1 AG06060, RO3 MH41435, and R23 NS24291.

REGIONAL AND SUBCELLULAR DISTRIBUTION OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE (PDE) ISOZYMES IN RAT BRAIN.

Methods.

Male Sprague Dawley rats (200-350g) were sacrificed by decapitation and brains rapidly removed and placed in cold Krebs-Ringer buffer, (pH 7.4) containing glucose. Larger brain areas, e.g. frontal cortex, neostriatum, substantia nigra, hippocampus, ventral tegmentum, and cerebellum were grossly dissected using a standard rat brain atlas. The locus coeruleus and dorsal raphe were isolated by taking 15 gauge punches from 0.5 to 0.75mm thick coronal cross-sections of brain. For regional distribution of PDE activities, brain tissue was homogenized with buffer conditions designed to minimize proteolysis (Adv. Cyclic Nucleotide Res. 10: 69-92, 1979) and aliquots assayed for the three PDE isozymes. For subcellular distribution studies, homogenates of the various brain regions were centrifuged at 30,000 x g, 15 min. with the resulting supernatants and pellets assayed for the three PDE isozymes. Cortical membranes were further fractionated by the method of Dodd et al. (Brain Res. 226:107-118, 1981).

Results

Regional and subcellular distribution of PDE isozymes [Type I (Ca^{2+} /calmodulin-sensitive), Type II (cGMP-activatable) and Type IV (high affinity cAMP specific)] was examined in eight rat brain regions. Substantia nigra (SN), neostriatum (NS), frontal cortex (FC), and hippocampus (HP) contained highest specific activity (S.A.) Type I and Type II PDE, while SN and NS contained highest S.A. Type IV PDE. Subcellular fractionation revealed Type I PDE is cytosolic in all brain regions, Type II PDE is predominately membrane-associated and Type IV PDE is distributed equally between compartments. Further fractionation of cortical membranes showed that Types II and IV PDE reside in synaptosomes. Combined studies using immunoprecipitation

and pharmacological selectivity indicate that the Type II PDE is the predominate form in synaptosomes. The results support the notion that different PDE isozymes exert preferential hydrolytic roles in various brain regions and subcellular compartments.

1988 APS/ASPET

ABSTRACT FORM

ABSTRACT MUST BE RECEIVED AT
MEETING OFFICE BY FRIDAY,
JUNE 3, 1988

MAILING ADDRESS OF FIRST AUTHOR

(Please print in black ink or type. Provide full name rather than initials.)

MICHAEL EUGENE WHALIN
DEPT. OF PHARMACOLOGY
COLLEGE OF MEDICINE MSB 3130
UNIVERSITY OF SOUTH ALABAMA
MOBILE, AL 36688

Office 205-460-6497

Phone: Home/Holiday _____

PRESENTATION PREFERENCE

Poster session

☐ Slide session

☒ Indifferent

Final decision will be at the discretion of the Program Committee.

SELECT CATEGORY NUMBERS & TITLES (SEE TOPIC CATEGORY LIST):

1st # 679-3 Title CYCLIC NUCLEOTIDES

2nd # 899-3 Title: MEMBRANE RECEPTORS
RECEPTOR-EFFECTOR

3rd # 903-3 Title: COUPLING

REGIONAL AND SUBCELLULAR DISTRIBUTION OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE (PDE) ISOZYMES IN RAT BRAIN. M.E. Whalin*, W.J. Thompson, R.L. Garrett, Jr.* and S.J. Strada
Dept. of Pharmacology, Univ. of South Alabama College of Medicine, Mobile, AL 36688.

The regional and subcellular distribution of PD isozymes [Type I (Ca²⁺/calmodulin-sensitive), Type II (cGMP sensitive) and Type IV (high affinity cAMP specific)] was examined in eight rat brain regions. Substantia nigra (SN), neostriatum (NS), frontal cortex (FC), and hippocampus (HP) contained highest specific activity Type I and Type II PDE, while SN and NS contained highest specific activity Type IV PDE. Subcellular fractionation revealed Type I PDE is cytosolic in all brain regions, Type II PDE is predominately membrane-associated and Type IV PDE is distributed equally between compartments. Further fractionation of cortical membranes showed that Types II and I PDE reside in synaptosomes. Combined studies using immunoprecipitation and pharmacological selectivity indicate that the Type II PDE is the predominate form in synaptosomes. The results support the notion that different PDE isozymes exert preferential hydrolytic roles in various brain regions and subcellular compartments. These studies were supported by grants from the USPHS (GM33538) and the USA (49620-85-K-0014).

All compounds that are designated by code or initial letters must be identified adequately in the abstract, e.g., MJ-1999: 4-(2-isopropylamino-1-hydroxyethyl) methanesulfonamide hydrochloride.

IMPORTANT

1. Prepare abstract carefully, on this form only.
2. Also fill out:
 - a. Presentation Preference
 - b. Topic category selection
 - c. Mailing address of first author
 - d. Signature block for member's signature
3. Return to APS/ASPET Meeting Office by June 3, 1988.
 - a. The original typed abstract form
 - b. 3 photocopies
 - c. Abstract handling fee - \$25
 - d. Program Confirmation/Customs Entry Letter
4. See over for complete instructions.

REMITTANCE

ABSTRACT HANDLING FEE \$25

Payable to APS/ASPET

Member of:

☐ APS, ☒ ASPET ☐ Guest Society _____
(Indicate Society)

Signing member, are you willing to chair a session?

() yes, category # _____

W. Joseph Thompson
Member's Name. Print or type.

Member's Signature

Telephone No. 205-460-6059

DO NOT FOLD THIS FORM

Mail to:
APS/ASPET Meeting Office
Room 3200
9650 Rockville Pike
Bethesda, Maryland 20814

- 250.15 SPATIAL AND TEMPORAL EXPRESSION OF mRNA ENCODING THE α SUBUNIT OF G_q : MAPPING IN RAT BRAIN BY IN SITU HYBRIDIZATION. R.E. Rasmussen, B.L. Largent, D.T. Jones, C. Frerking, P.E. Winkler, and J.H. Snyder. (SPON: K. Brown) Dept. of Molecular Biology and Genetics, Howard Hughes Medical Institute, and Dept. of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.

The G -proteins represent a family of proteins that bind guanine nucleotides and actively participate in many signal transduction processes. Members of this G -protein family are highly conserved at the protein and nucleotide level. To distinguish in our studies among various members of this family, we generated specific oligonucleotide probes to unique 3' untranslated regions of each G -protein cDNA. These probes were used to detect mRNA abundance and distribution in rat brain. The oligonucleotide probes were labeled using a novel technique involving the synthesis of a Shiner oligonucleotide containing 46 nucleotides of target-specific sequence followed by an additional 12 nucleotides (CAR: common acceptor region). A second oligonucleotide (Ziner), consisting of T₁₉ followed by the sequence complementary to the CAR region, was annealed to the Shiner oligo and extended with α -³²P-ATP and DNA polymerase. These probes of defined specific activity and uniform length were then used for *in situ* hybridization studies.

G_q , the stimulatory G -protein, is associated with the receptor-mediated activation of adenylyl cyclase, an enzyme abundant in neural tissues and essential for many types of neurotransmission. Mapping of mRNA encoding the α subunit of G_q reveals abundant hybridization and heterogeneous distribution throughout the brain. Control studies confirm the hybridization specificity. G_q mRNA is prevalent throughout the brain, being particularly evident in large neurons such as pyramidal cells of the piriform cortex and hippocampus, and neurons of motor nuclei and reticular formation. Interestingly, the general pattern of hybridization is quite similar to the immunocytochemical distribution of calcineurin (K. Brown, et al., J. Neurosci., 6:1952-1961, 1986). Localization of G_q message does not parallel [³H]flunitrazepam binding (a marker for G_q -coupled adenylyl cyclase) in a fashion that might be expected. Notably, cells of the cerebral cortex, where neurons contain the highest levels of adenylyl cyclase in the brain, demonstrate the lowest abundance of G_q mRNA. This mismatch may suggest that adenylyl cyclase does not exclusively couple through G_q . Alternatively, G_q in other areas of the brain may effect transduction through other second messenger enzymes. Presently, we are examining the modulation of G_q message levels after intracerebral injection of the bacterial toxin cholera and pertussis, known to covalently modify G subunits. Additionally, the ontogeny of G_q mRNA in embryonic and neonatal brain is being assessed.

- 250.16 BINDING OF GUANINE NUCLEOTIDE ANALOGUES TO ADENYLYL CYCLASE REGULATORY PROTEINS IN MEMBRANE CELL PREPARATIONS. J.M. Gorman, M.H. Marshall, and M.H. Rasmussen. The Chicago Med Sch., Chicago, IL 60606 and Dept Physiol and Biophys. U. of Illinois College of Med., Chicago, IL 60607.

Neural cell membranes, when exposed to hydrolysis-resistant analogues of GTP, show a dose-dependent stimulation or inhibition (depending upon assay conditions) of adenylyl cyclase (AC). The activation or inhibition of AC parallel subsequent to washing of membranes and is independent of neurotransmitter(s). Although the binding of GTP analogues to detergent-solubilized and purified guanine nucleotide binding regulatory proteins (GN) has been studied, the kinetics of guanine nucleotide binding to individual GN in membranes has not been characterized.

Rat cerebral cortex membranes were incubated with either varying concentrations of the hydrolysis-resistant, photoaffinity GTP analogs, azidoanilide GTP (³²P-AGTTP) or with a constant amount of ³H-AGTTP and varying concentrations of cold GTP analogues. Membranes were incubated for 3 min at 23°C, centrifuged, resuspended in fresh buffer and exposed to UV irradiation for 3 min. Following irradiation the suspension was centrifuged. The resulting pellet was dissolved in sample buffer, subjected to SDS-PAGE and radioautography. Radioactive bands corresponding to AC stimulatory GN (32 and 42 kDa bands; GN₁ and GN₂), inhibitory GN (40 kDa doublet composed of GN₃ and GN₄) and a novel neural GN (32 kDa band; GN₅) were eluted from the dried gels and the amount of radioactivity quantitated.

Isotach analysis revealed that the GN_{1/2} band had the highest affinity for ³H-AGTTP, $K_D = 2.12 \pm 0.36$ nM (mean $\pm$ SE), followed by GN₃ (3.59 $\pm$ 0.39), GN₄ (4.87 $\pm$ 0.64) and GN₅ (5.70 $\pm$ 1.23). Separation of the GN_{1/2} doublet into its components (i.e., GN₁ and GN₂) indicated that these two GN were not significantly different in their binding affinity for nucleotides. Analysis of competition assays indicated that all of the guanine nucleotides studied were similar to AGTTP as they all displayed the highest affinity for the GN_{1/2} band and the lowest affinity for the GN₅. Of the GTP analogues studied GTPPP displayed the highest affinity for all GN followed by GTPS, GTP, and AGTTP. GTPPP and AGTTP displayed a significantly higher affinity for GN_{1/2} than GN₃; whereas GTPS, GTP and GTP (which is rapidly hydrolyzed to GMP) displayed nearly equal affinity for both proteins. Whether these observations are a result of assay conditions or innate affinities is not known at this time. These data indicate that components of synaptic membranes may alter apparent affinity of GN for nucleotides and that the activation/inhibition of AC is a dynamic process with multiple sites of regulation.

- 250.17 ISOLATION AND CHARACTERIZATION OF THE INOSITOL 1,4,5 TRISPHOSPHATE (IP₃) BINDING SITE. S. Supattapone, P. Worley, J. Saragban and S.H. Snyder. Department of Neuroscience, Johns Hopkins Univ. Sch. of Med., Baltimore, MD 21205

IP₃ appears to be the second messenger responsible for mobilizing calcium from internal stores (Berridge, M.J., and Irvine, R.F. Nature, 312:315, 1984). Therefore, it would be of interest to characterize the binding site for IP₃ in the cell. Previous reports (Worley, P.L., et al., Nature, 325:139, 1987) have demonstrated that the rat cerebellum is a very abundant source of a high affinity IP₃ binding site.

In this study, we have solubilized and purified the IP₃ binding site to apparent homogeneity from rat cerebellum. The purified receptor is globular and has a Stokes' radius of 18 nm. Therefore, its molecular weight is on the order of one million daltons. While IP₃ binding is reversibly inhibited by 300 nM calcium in crude homogenates and solubilized membranes, the purified binding site is not inhibited by calcium concentrations up to 1.5 μ M. Inhibition by calcium could be reconstituted by addition of crude solubilized cerebellar membranes, but not by the cytosolic fraction of cerebellum.

- 250.18 IDENTIFICATION AND PURIFICATION OF BRAIN TYPE II PHOSPHODIESTERASE: A DISTINCT GMP RECEPTOR PROTEIN IN MAMMALIAN BRAIN MEMBRANES. G.H. Molloy, M.A. Innes, and S.J. Strass. (SPON: M.L. Longenecker). University of South Alabama, Dept. of Pharmacology, College of Medicine, Mobile, AL 36688.

Type II (cGMP stimulated) cyclic nucleotide phosphodiesterase (PDE) as purified from heart, liver, and adrenal tissues shows a preference for cGMP as substrate and displays enhanced cAMP hydrolysis by low physiological concentrations of cGMP. Our studies of brain Type II PDE indicate it to be the majority of the hydrolytic activity found in membrane fractions. It is not released by either hypotonic or high ionic strength buffers. Detergent solubilization of the Type II PDE does not preserve its regulation by cGMP. However, if released by limited proteolysis using TPCK-trypsin, full cGMP regulation is retained. The solubilized enzyme was purified to apparent homogeneity, utilizing DEAE-cellulose ion exchange, cAMP assay-spharose 4B, and hydroxyapatite chromatography. A 3000 fold increase in specific activity was observed. Its M_r is 240 kD by gel filtration. The subunit M_r of the enzyme determined by SDS-PAGE analysis (7.5X) shows a major protein band at 103-105 kD. Maximum velocities are 137 U/mg and 139 U/mg for cAMP and cGMP respectively. $S_{0.5}$ are 28 μ M for cAMP and 16 μ M for cGMP. The K_{act} for cGMP stimulation of cAMP hydrolysis at 3 μ M substrate is 0.22 μ M and maximum stimulation (2 fold) is achieved at 2 μ M cGMP. The purified enzyme is phosphorylated by the catalytic subunit of cAMP dependent protein kinase and retains the same subunit M_r . Phosphorylation does not appear to affect cAMP hydrolysis at 3 μ M substrate in the absence or presence of 2 μ M cGMP, but does reduce cGMP hydrolysis measured at 40 μ M substrate by 30%. Monoclonal antibodies produced against purified Type II PDE immunoprecipitate enzyme activity (90%) with the immunoprecipitate retaining full regulation by cGMP. Immunocytochemical studies are being pursued to define the regional distribution and localization of the Type II PDE observed by activity analysis in related studies (Barrett et al., this volume). This enzyme may constitute a major cGMP receptor and may serve an important regulatory role in controlling the level of cyclic nucleotides during neuronal function. These studies were supported by USPHS (GM 33538) and a contract from the U.S. Air Force (49620-85-K-0014).

DIFFERENTIAL SENSITIVITY TO CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS IN RAT BRAIN CORTICAL SLICES.



These studies are examining the effects of various cyclic nucleotide phosphodiesterase inhibitors on the turnover rate of cyclic AMP in brain slices after stimulation of different receptor systems.

PROCEDURE:

Male, Sprague-Dawley rats (200-225g) were killed by decapitation, the brains rapidly removed into ice-cold buffer (10mM Hepes, 154mM NaCl, pH 7.4), and the cortex excised. Slices were prepared using a McIlwain chopper (0.22mm setting), then transferred to oxygenated Krebs-Ringer buffer containing glucose maintained at 37°C for a 15 min. equilibration period, during which the buffer was changed three times. The slices were then incubated for one hr. with [³H]-adenine, then washed and incubated with maximally effective concentrations of 20uM isoproterenol (ISO) or 50uM adenosine for 12.5 min. After settling, 50ul of slices were rapidly transferred into buffer containing 200uM propranolol or 0.55 units adenosine deaminase, and 80uM drug or equivalent volume of DMSO. This incubation period was stopped by the addition of an equal volume of 10% TCA at varying time points ranging from 1-20 min. Following homogenization, the samples were centrifuged at 20,000xg for 10 min., the cAMP extracted from the supernatant and isolated by the Dowex AG50/Alumina double column method, and the λ conversion and decay constant determined as described by Barber et al. (Mol. Pharm. 32:753, 1987). (The decay constant is the negative slope of the straight line obtained by plotting the natural log of the response (λ conversion - basal) versus time.)

RESULTS:

Rolipram was the best inhibitor of cAMP decline in both receptor systems, showing 60% inhibition following adenosine stimulation of cAMP levels, and >90% inhibition in the ISO system. Other PDE-inhibitors tested (eg. HL-725, SQ-65442) also showed greater efficacy against decline in cAMP levels following ISO stimulation than adenosine stimulation, while some (eg. Ro 20-1724) did not appear to discriminate between the two systems. Some drugs (e.g. RS-82856, LY-195115) were poor inhibitors in both systems. This variation in inhibitor susceptibility may indicate the involvement of separate PDE isoenzymes linked to different agonist receptor systems.



The effect of various drugs (80 μ M) on the decay rate of cAMP in rat cortical slices was measured according to the procedure described in "methods". Baclofen does not appear to significantly affect the cAMP decay rate compared to known PDE inhibitors.

1988 APS/ASPET

ABSTRACT FORM

ABSTRACT MUST BE RECEIVED AT
MEETING OFFICE BY FRIDAY,
JUNE 3, 1988

MAILING ADDRESS OF FIRST AUTHOR

(Please print in black ink or type. Provide full name rather than initials.)

Robert L. Garrett, Jr., PhD
DEPT. OF PHARMACOLOGY
UNIVERSITY OF SOUTH ALABAMA
COLLEGE OF MEDICINE
MOBILE, AL 36608

Office 205 460-6061

Phone: Home/Holiday 205 460-6497

PRESENTATION PREFERENCE

- ☐ Poster session
☐ Slide session
☒ Indifferent

Final decision will be at the discretion of the Program Committee.

SELECT CATEGORY NUMBERS & TITLES (SEE TOPIC CATEGORY LIST):

1st # 679-3 Title: Cyclic Nucleotides

2nd # 903-3 Title: Receptor-Effector Linkage

3rd # 900-3 Title: Neurotransmitter Receptors

DIFFERENTIAL SENSITIVITY TO CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS IN RAT BRAIN CORTICAL SLICES. R. Garrett, Jr.*, W.J. Thompson, M.E. Whalin* and S.J. Strada. Dept. of Pharmacology, Univ. of South Alabama College of Medicine, Mobile, AL 36688.

The effects of selective cyclic nucleotide phosphodiesterase (PDE) inhibitors on the rate of cyclic AMP (cAMP) turnover were examined in male, rat cortical slices. The conversion of [³H]-labeled adenine nucleotide pools in cAMP was determined after stimulation with maximally effective concentrations of isoproterenol (ISO) and adenosine (AD). The decay constant was measured according to Barber et al. (Mol. Pharm. 32:753, 1987) using the addition of either 200 µM propranolol or 0.55 units of deaminase to terminate the agonist response. Rolipram, the best inhibitor of cAMP decline in both receptor systems. However, the drug showed only 60% inhibition following stimulation of cAMP levels, while >90% inhibition in the ISO stimulated system. Other PDE-inhibitors tested (e.g., HL-725, SQ-65442) also showed greater efficacy against the decline in cAMP levels following ISO than after AD. Some drugs (e.g., RS-82856, LY-195115) were poor inhibitors and also did not discriminate between the two systems. The variation in inhibitor sensitivity may indicate the involvement of separate PDE isozymes linked to different agonist receptor systems. These studies were supported by grants from the USPHS (GM 33538) and the USAF (49620-85-K-0014).

All compounds that are designated by code or initial letters must be identified adequately in the abstract, e.g., MJ-1999: 4-(2-isopropylamino-1-hydroxyethyl) methanesulfonamide hydrochloride.

IMPORTANT

1. Prepare abstract carefully, on this form only.
2. Also fill out:
 - a. Presentation Preference
 - b. Topic category selection
 - c. Mailing address of first author
 - d. Signature block for member's signature
3. Return to APS/ASPET Meeting Office by June 3, 1988.
 - a. The original typed abstract form
 - b. 3 photocopies
 - c. Abstract handling fee - \$25
 - d. Program Confirmation/Customs Entry Letter
4. See over for complete instructions.

REMITTANCE

ABSTRACT HANDLING FEE \$25

Payable to APS/ASPET

Member of:

☐ APS, ☒ ASPET ☐ Guest Society (indicate Society)

Signing member, are you willing to chair a session?

(X) yes, category # 679-3

Samuel J. STRADA, Ph.D.
Member's Name. Print or type.

Samuel J. Strada
Member's Signature

Telephone No. 205 460-6497

DO NOT FOLD THIS FORM

Mail to:
APS/ASPET Meeting Office
Room 3200
9650 Rockville Pike
Bethesda, Maryland 20814

EXHIBIT B: PUBLISHED SCIENTIFIC REPORTS AND MANUSCRIPTS

Rapid Communication

γ -Aminobutyric Acid_B Receptor Activation Modifies Agonist Binding to β -Adrenergic Receptors in Rat Brain Cerebral Cortex

Roberta W. Scherer, John W. Ferkany, E. William Karbon, and S. J. Enna

Nova Pharmaceutical Corporation, Baltimore, Maryland, U.S.A.

Abstract: The interaction of isoproterenol with β -adrenergic receptor (β AR) binding sites was measured in membranes prepared from rat brain cerebral cortical slices previously incubated in the presence or absence of γ -aminobutyric acid (GABA) receptor agonists. Both GABA and baclofen, but not isoguvacine, altered β AR agonist binding by increasing the affinity of both the low- and high-affinity binding sites and by increasing the proportion of low-affinity receptors. The response to baclofen was stereoselective, and the effect of GABA was not inhibited by bicuculline. The results suggest that GABA_B, but not GABA_A, receptor activation modifies the coupling between β AR and stimulatory guanine nucleotide-binding protein, which may in part explain the ability of baclofen to augment isoproterenol-stimulated cyclic AMP accumulation in brain slices. **Key Words:** γ -Aminobutyric acid—Baclofen— β -Adrenergic receptor—Isoproterenol—GABA_B receptors—Brain membranes—Cyclic AMP. Scherer R. W. et al. γ -Aminobutyric acid_B receptor activation modifies agonist binding to β -adrenergic receptors in rat brain cerebral cortex. *J. Neurochem.* 53, 989–991 (1989).

There are at least two receptor subtypes for γ -aminobutyric acid (GABA): GABA_A and GABA_B. The GABA_A receptors are associated with Cl⁻ flux (Enna and Gallagher, 1983), whereas GABA_B receptor activation alters K⁺ and Ca²⁺ channels (Gahwiler and Brown, 1985; Feltz et al., 1987) and modifies second messenger production. With regard to second messengers, baclofen, a selective GABA_B receptor agonist (Hill and Bowery, 1981), augments neurotransmitter-stimulated cyclic AMP accumulation in brain slices while having no direct effect on second messenger formation (Hill, 1985; Karbon and Enna, 1985; Watling and Bristow, 1986). The findings that baclofen reduces adenylate cyclase activity in brain homogenates and diminishes forskolin-stimulated cyclic AMP production in rat brain slices (Wojcik and Neff, 1984; Karbon and Enna, 1985) suggest the existence of pharmacologically distinct subsets of GABA_B receptors (Scherer et al., 1988).

Although the GABA_B receptor-mediated inhibition of adenylate cyclase in homogenates appears to be mediated by a guanine nucleotide binding protein (G_i or G_o) (Xu and Wojcik, 1986), the cellular components associated with the cyclic AMP-augmenting response to baclofen are unknown (Karbon and Enna, 1985). In addition to increasing the amount of neurotransmitter-stimulated cyclic AMP, baclofen increases the potency of neurotransmitters to stimulate accumulation of this second messenger in brain (Karbon et al., 1984; Karbon and Enna, 1985). Because receptor-mediated cyclic AMP production requires the coordinated action of several factors—including the receptor, the stimulatory and inhibitory guanine nucleotide-binding proteins (G_s and G_i), and the catalytic unit of adenylate cyclase (Allende, 1988)—it is conceivable that baclofen modifies this system by influencing one or more of these components. Given the observation that baclofen may influence the potency of receptor agonists to stimulate cyclic AMP accumulation, the present study was undertaken to examine the effect of GABA_B agonists on β -adrenergic receptor (β AR) agonist binding in rat brain cerebral cortical membranes.

MATERIALS AND METHODS

Male Sprague-Dawley rats (Charles River), weighing 200–300 g, were decapitated, and the brains were removed and placed into ice-cold HEPES-buffered saline (154 mM NaCl and 10 mM HEPES, pH 7.4). The frontal cortex was dissected, blotted dry, and weighed. Portions of tissue (40–100 mg wet weight) were minced with a McIlwain tissue chopper (0.26 × 0.26 mm) and immediately placed into vials containing 5 ml of Krebs-Ringer-bicarbonate buffer (37°C), aerated with 95% O₂/5% CO₂, of the following composition (in mM): NaCl, 118; KCl, 5; KH₂PO₄, 1.2; MgSO₄, 1.2; CaCl₂, 1.2; NaHCO₃, 25; and D-glucose, 11.1. Either vehicle (50 μ l)

Received May 23, 1989; accepted June 8, 1989.

Address correspondence and reprint requests to Dr. E. W. Karbon at Nova Pharmaceutical Corp., 6200 Freeport Centre, Baltimore, MD 21224, U.S.A.

Abbreviations used: β AR, β -adrenergic receptor; GABA, γ -aminobutyric acid; G_i and G_s, inhibitory and stimulatory guanine nucleotide-binding proteins, respectively.

or test substance was added to the slice-containing solution and incubated for 10 min. The aqueous portion was aspirated, and the slices were homogenized (Brinkmann Polytron, setting of 5.5 for 5–10 s) in 5 ml of HEPES buffer (1 mM Na₂EDTA and 2 mM HEPES, pH 7.5) containing the same concentration of test agent. The homogenate was centrifuged (48,000 g, 10 min), and the pellet was resuspended and washed three additional times in a similar manner before suspension (6.5 mg of tissue/ml) in Tris-buffered saline (154 mM NaCl, 2.5 mM MgCl₂, and 20 mM Tris, pH 7.4) (O'Donnell et al., 1984).

Saturation binding of [¹²⁵I]iodopindolol was performed with radioligand concentrations ranging from 10 to 1,000 pM (O'Donnell et al., 1984). Specific binding was defined as that portion of the total binding displaced by 100 μ M isoproterenol. The samples were incubated for 30 min at 37°C, and the reaction was terminated by addition of 5 ml of ice-cold Tris buffer and filtration over GF/B filters in a Brandel cell harvester. The filters were washed four times each with 4 ml of buffer, after which radioactivity was quantified using a gamma counter.

Competition experiments were conducted with 100 pM [¹²⁵I]iodopindolol and isoproterenol concentrations ranging from 0.1 to 10,000 nM. Least squares analysis was performed using Lunden 2 (Lunden Software, Chagrin Falls, OH, U.S.A.). Two binding sites were deemed more likely than one if the *F* statistic for the former was associated with a *p* value of ≤ 0.05 .

To assess accurately the effect of GABA agonists on β AR agonist binding, the data from drug-treated tissue were compared only with control data obtained in parallel experiments. Therefore, on a given day, all tissue slices originated from the same pool of tissue. Statistical analysis was performed using a two-tailed Student's *t* test. Differences were considered significantly different for a *p* value of ≤ 0.05 .

Protein concentrations were determined using reagent kits from Bio-Rad (Richmond, CA, U.S.A.).

Baclofen (D,L-, D-, and L-) was kindly supplied by Ciba-Geigy (Summit, NJ, U.S.A.). [¹²⁵I]iodopindolol was purchased from New England Nuclear (Boston, MA, U.S.A.), and isoproterenol, bicuculline methiodide, and GABA were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Isoguvacine was purchased from Research Biochemicals, Inc. (Natick, MA, U.S.A.).

RESULTS

In control rat brain cortical membranes, the *K_D* for [¹²⁵I]iodopindolol binding was 86 pM, and the receptor density was 150 fmol/mg of protein. Competition experiments with isoproterenol yielded shallow displacement curves. When examined using least squares analysis, the data were best described by a two-site model. Under these assay conditions, the equilibrium dissociation constants for the low- (*K_L*) and high- (*K_H*) affinity states for isoproterenol ranged from 148 to 234 and 21 to 40 nM, respectively (Table 1). Exposure of brain slices to D,L-baclofen (100 μ M) increased the affinity of both the high- and low-affinity states for isoproterenol. The percentage of low-affinity agonist binding sites increased nearly 50% following exposure to the GABA_B agonist, whereas the percentage of high-affinity sites was significantly reduced (Table 1). Exposure of cortical slices to baclofen did not affect [¹²⁵I]iodopindolol binding affinity (*K_D* = 84 pM), nor did the GABA_B agonist influence β AR binding when added directly to membranes prepared from slices exposed to vehicle alone (data not shown).

The effect of baclofen was stereoselective, with L-baclofen (10 μ M) and the racemate altering β -adrenergic agonist binding, whereas D-baclofen (10 μ M) was ineffective. Exposure to 1 μ M L-baclofen shifted the proportion of low- and high-affinity agonist binding sites, without causing a significant change in receptor affinity.

When cortical slices were incubated in the presence of 25 μ M GABA, the competition curve for isoproterenol was best described as a single site with intermediate affinity (Table 2). Bicuculline (50 μ M), a GABA_A receptor antagonist, did not attenuate the response to GABA, and isoguvacine (20 μ M), a selective GABA_A receptor agonist, had no effect on β AR binding (Table 2).

DISCUSSION

The results of this study indicate that exposure of rat brain cerebral cortical slices to GABA_B, but not GABA_A, receptor agonists alters β AR agonist binding. Agonist attachment to both low- and high-affinity sites is enhanced by GABA_B agonists, as is the proportion of the low-affinity receptors.

Under control conditions, the displacement curve repre-

TABLE 1. Stereoselective effect of baclofen preincubation on isoproterenol displacement of [¹²⁵I]iodopindolol binding to rat brain cerebral cortical membranes

Condition (n)	<i>K_H</i> (nM)	<i>K_L</i> (nM)	% <i>K_H</i>	% <i>K_L</i>
Control (7)	26 $\pm$ 3	222 $\pm$ 31	54.4 $\pm$ 6	45.6 $\pm$ 6
100 μ M D,L-baclofen (8)	12 $\pm$ 2 ^a	134 $\pm$ 12 ^a	32.2 $\pm$ 6 ^a	67.8 $\pm$ 6 ^a
Control (5)	40 $\pm$ 5	234 $\pm$ 21	57.7 $\pm$ 9	42.3 $\pm$ 9
10 μ M L-baclofen (5)	12 $\pm$ 2 ^a	135 $\pm$ 12 ^a	25.9 $\pm$ 5 ^a	74.1 $\pm$ 5 ^a
10 μ M D-baclofen (4)	45 $\pm$ 5	237 $\pm$ 54	52.2 $\pm$ 6	47.8 $\pm$ 6
Control (4)	21 $\pm$ 2	148 $\pm$ 16	34.2 $\pm$ 1	65.8 $\pm$ 1
1 μ M L-baclofen (5)	16 $\pm$ 4	119 $\pm$ 12	22.8 $\pm$ 3 ^a	77.2 $\pm$ 3 ^a

Competition by isoproterenol against [¹²⁵I]iodopindolol binding was measured in membranes prepared from rat brain cerebral cortical slices incubated for 10 min in the absence (control) or presence of baclofen. Data are mean $\pm$ SEM values from four to eight separate experiments (shown in parentheses). The data from drug-treated groups were compared only with control data obtained from experiments done in parallel. *K_H* and *K_L* are the dissociation constants for isoproterenol at the high- and low-affinity sites, respectively, whereas % *K_H* and % *K_L* are the percentages of isoproterenol bound to the high- and low-affinity sites, respectively.

^a Significantly different from the corresponding control (*p* < 0.05 by Student's two-tailed *t* test).

TABLE 2. Effect of GABAergic compounds on isoproterenol displacement of [¹²⁵I]iodopindolol binding to rat brain cerebral cortical membranes

Condition (n)	K _H (nM)	K _L (nM)	% K _H	% K _L
Control (5)	17 ± 2	195 ± 25	33.9 ± 5	66.1 ± 5
25 μ M GABA (4)	^a	92 ± 12 ^b	^a	95.6 ± 4 ^b
20 μ M isoguvacine (5)	18 ± 4	183 ± 9	33.1 ± 5	66.9 ± 5
50 μ M bicuculline (5)	20 ± 4	199 ± 13	41.5 ± 5	58.5 ± 5
GABA + bicuculline (4)	^a	119 ± 24 ^b	^a	92.8 ± 6 ^b

Competition by isoproterenol against [¹²⁵I]iodopindolol was measured in membranes prepared from rat brain cerebral cortical slices incubated for 10 min in the absence (control) or presence of various agents. Data are mean $\pm$ SEM values from four or five separate experiments (shown in parentheses). In a given experiment, all of the drug-treated groups were examined simultaneously with controls. K_H and K_L are the dissociation constants for isoproterenol at the high- and low-affinity sites, respectively, whereas % K_H and % K_L are the percentages of isoproterenol bound to the low- and high-affinity sites, respectively.

^a In three of four experiments, the curve was best fitted by a single-site model.

^b Significantly different from the control ($p < 0.05$ by Student's two-tailed t test).

senting the interaction of isoproterenol with [¹²⁵I]iodopindolol binding was quite shallow, a result indicating multiple sites (O'Donnell et al., 1984). Previous reports (DeLean et al., 1980) suggested that β AR agonists bind with low affinity to an uncoupled receptor, whereas high-affinity binding reflects the formation of a ternary complex comprising agonist, β AR, and G_s. The finding that GABA_B receptor activation enhances β AR agonist binding suggests that GABA modifies β AR-G_s coupling. This effect could result from an alteration in a region of the β AR that is common to G_s-coupled receptors and is involved in receptor-G_s coupling or from an effect on G_s itself. Both of these possibilities are consistent with the finding that GABA_B receptor activation enhances the cyclic AMP response to many substances, such as adenosine and vasoactive intestinal peptide, which stimulate G_s-coupled receptors in rat brain slices.

Although the absolute changes in β AR agonist affinity seen in response to GABA_B receptor activation are small, they are potentially biologically relevant. For example, exposure of brain membranes to GTP, which is absolutely required for neurotransmitter-stimulated cyclic AMP production, causes only a two- to threefold shift in β AR agonist affinity (O'Donnell et al., 1984). Moreover, it is possible that GABA_B receptor activation elicits a much larger shift in β AR agonist affinity, a portion of which is lost during the membrane preparation.

The cyclic AMP response observed in cortical slices following incubation with catecholamines and GABA_B receptor agonists and the GABA_B receptor-mediated shift in β AR agonist binding share some common features. In both cases, adrenergic agonist affinity is enhanced (Karbon et al., 1984; Karbon and Enna, 1985). In addition, an intact tissue preparation is required to detect either the cyclic AMP-augmenting response or the shift in β AR agonist binding. These data suggest a causal relationship between changes in β AR agonist binding and the cyclic AMP-augmenting response. In any event, the present findings provide additional evidence supporting a neuromodulatory role for GABA in brain and illustrate the functional importance of receptor-receptor interactions.

Acknowledgment: This work was sponsored by the U.S. Air Force Office of Scientific Research under contract F49620-87-C-0071. The U.S. Government is authorized to reproduce and distribute reprints for governmental purposes not withstanding any copyright notation hereon.

REFERENCES

- Allende J. E. (1988) GTP-mediated macromolecular interactions: the common features of different systems. *FASEB J.* 2, 2356-2367.
- DeLean A., Stadel J. M., and Lefkowitz R. J. (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. *J. Biol. Chem.* 255, 7108-7117.
- Enna S. J. and Gallagher J. P. (1983) Biochemical and electrophysiological characteristics of GABA receptors, in *International Review of Neurobiology*, Vol. 24, pp. 181-212. Academic Press, New York.
- Feltz A., Demeneix B., Feltz P., Taleb O., Trouslard J., Bossu J.-L., and DuPont J.-L. (1987) Intracellular effectors and modulators of GABA-A and GABA-B receptors: a commentary. *Biochimie* 69, 395-406.
- Gahwiler B. H. and Brown D. A. (1985) GABA_B receptor-activated potassium current in voltage-clamped CA1 pyramidal cells in hippocampal cultures. *Proc. Natl. Acad. Sci. USA* 82, 1558-1562.
- Hill D. R. (1985) GABA_B receptor modulation of adenylate cyclase activity in rat brain slices. *Br. J. Pharmacol.* 84, 249-257.
- Hill D. R. and Bowery N. G. (1981) ³H-Baclofen and ³H-GABA bind to bicuculline-insensitive GABA_B in rat brain. *Nature* 290, 149-152.
- Karbon E. W. and Enna S. J. (1985) Characterization of the relationship between gamma-aminobutyric acid B agonists and transmitter-coupled cyclic nucleotide-generating systems in rat brain. *Mol. Pharmacol.* 27, 53-59.
- Karbon E. W., Duman R. S., and Enna S. J. (1984) GABA_B receptors and norepinephrine-stimulated cyclic AMP production in rat brain cortex. *Brain Res.* 306, 327-332.
- O'Donnell J. M., Wolfe B. B., and Frazer A. (1984) Agonist interactions with beta-adrenergic receptors in rat brain. *J. Pharmacol. Exp. Ther.* 228, 640-647.
- Scherer R. W., Ferkany J. W., and Enna S. J. (1988) Evidence for pharmacologically distinct subsets of GABA_B receptors. *Brain Res. Bull.* 21, 429-443.
- Watling K. J. and Bristow D. R. (1986) GABA_B receptor-mediated enhancement of vasoactive intestinal peptide-stimulated cyclic AMP production in slices of rat cerebral cortex. *J. Neurochem.* 46, 1755-1762.
- Wojcik W. J. and Neff N. H. (1984) Gamma-aminobutyric acid B receptors are negatively coupled to adenylate cyclase in brain and in the cerebellum these receptors may be associated with granule cells. *Mol. Pharmacol.* 25, 24-28.
- Xu J. and Wojcik W. J. (1986) Gamma-aminobutyric acid B receptor-mediated inhibition of adenylate cyclase in cultured cerebellar granule cells: blockade by islet activating protein. *J. Pharmacol. Exp. Ther.* 239, 568-573.

**Pharmacological and Biochemical Evidence for the Existence of Multiple GABA_B Receptor
Subpopulations in Central Nervous System**

E.W. Karbon¹, S.H. Zorn², R.J. Newland³ and S.J. Enna¹

**¹Nova Pharmaceutical Corporation, Baltimore, MD; ²Pfizer Central Research, Groton, CT; and
³Glassboro State College, Glassboro, NJ**

INTRODUCTION

A common feature of many neurotransmitter substances is their ability to interact with multiple receptors. For example, norepinephrine activates both α - and β -adrenoceptors, each of which may be subdivided further on the basis of functional properties and pharmacological selectivity. Similarly, acetylcholine acts upon nicotinic and as many as five different muscarinic receptors. The existence of receptor subtypes allows for a limited number of neurotransmitter and neuromodulatory substances to regulate an extensive array of cellular processes.

Amino acid neurotransmitters such as γ -aminobutyric acid (GABA) and glutamic acid also interact with multiple receptors. For GABA, there appear to be at least two receptor subtypes, GABA_A and GABA_B. The GABA_A sites mediate changes in chloride ion conductance, are activated by muscimol and THIP and inhibited by bicuculline and picrotoxin. In contrast, GABA_B receptors are bicuculline- and THIP-insensitive and are stereoselectively activated by β -p-chlorophenyl GABA (baclofen). Indeed, as described in the present report, there are now data suggesting a multiplicity of pharmacologically distinct GABA_B receptors.

PROPERTIES OF GABA_B RECEPTORS

The GABA_B receptor was initially proposed when it was found that GABA inhibited neurotransmitter release at peripheral sites such as atria, and attenuated electrically-induced smooth muscle contractions in a bicuculline-

insensitive manner. Moreover, these effects are mimicked by baclofen, but not by THIP. While the physiological relevance of peripheral GABA_B receptors is unclear since most organs do not possess GABAergic neurons, these studies pointed to the possible existence of a population of GABA receptors that differed pharmacologically from the classical GABA binding site. Shortly after their discovery in peripheral tissues, GABA_B receptors were identified in the central nervous system when baclofen was shown to inhibit potassium-stimulated neurotransmitter release from brain slices. Clinically, baclofen is employed as an antispastic agent in the treatment of multiple sclerosis (Table 1). Baclofen has also been reported to display analgesic properties, although it is sedating at doses that significantly elevate the pain threshold.

Both in vivo and in vitro, baclofen displays a number of effects on various organ systems (Table 1). The ability of baclofen to inhibit electrically-induced intestinal smooth muscle contractions is particularly interesting inasmuch as GABA is highly concentrated in enteric neurons that synapse upon acetylcholine-containing cells, regulating acetylcholine release. Both baclofen and GABA inhibit electrically-evoked contractions of isolated guinea pig trachea, and attenuate vagally-mediated bronchoconstriction in anesthetized guinea pigs. These findings suggest that selective GABA_B receptor agents might be useful for treating certain pulmonary or gastrointestinal disorders as well as for modifying central nervous system activity. The variety of effects produced by baclofen raises the question as to whether they are mediated by a single population of receptors, or by pharmacologically distinct subpopulations of GABA_B sites.

MULTIPLICITY OF GABA_B RECEPTORS

Following the identification of GABA_B receptors, GABA_B binding sites were characterized in brain membranes using radioligand binding assays. It was found that [³H]GABA labels both low and high affinity GABA_B sites, and that [³H](+)-baclofen, the pharmacologically active enantiomer, also detects low and high affinity sites. Whereas the ratio of low to high affinity GABA_B binding does not differ substantially among rat brain regions, destruction of the dorsal noradrenergic bundle selectively reduces the number of lower affinity GABA_B binding sites, suggesting kinetically distinct populations of GABA_B receptors.

Additional evidence favoring the existence of multiple GABA_B subpopulations receptors was obtained from studies aimed at determining the effector mechanism(s) associated with these sites (Table 2). In rat brain membranes, baclofen inhibits basal and forskolin-stimulated adenylate cyclase activity, decreasing cyclic AMP formation. Thus, GABA_B receptors appear similar to α₂-adrenergic, muscarinic cholinergic, and adenosine A₁, which reduce adenylate cyclase activity by coupling with G_i, the inhibitory guanine nucleotide binding protein. A distinguishing characteristic of G protein-coupled receptors is that agonist binding affinity is reduced in the presence of GTP, which attaches to a regulatory site on the α-subunit of the G-protein. As would be predicted from the cyclase data, GABA_B receptor binding is attenuated by GTP which reduces the affinity of GABA_B recognition sites for the radioligand.

Additional evidence favoring an association of GABA_B receptors with G_i was provided by the finding that islet activating protein (IAP, pertussis toxin), which prevents receptor-G_i interactions, prevents baclofen from inhibiting adenylate cyclase. Likewise, treatment of brain membranes with activated IAP inhibits GABA_B receptor binding, an effect that is reversed by the addition of purified G_i.

While these results suggest that GABA_B receptors are negatively coupled to adenylate cyclase, studies performed with brain slices suggest that GABA can increase brain cyclic AMP levels (Table 2). Thus, in many rat brain regions, including cerebral cortex, hippocampus, and striatum, baclofen enhances neurotransmitter-stimulated cyclic AMP accumulation while having no effect on second messenger formation itself. The response to baclofen is restricted to the (+) isomer, is mimicked by GABA, and is bicuculline-insensitive (Figure 1). This augmenting response is observed using a variety of agents to stimulate cyclic AMP production, including isoproterenol, norepinephrine, adenosine, 2-chloroadenosine, and vasoactive intestinal peptide. While the precise mechanism responsible for the augmentation is unknown, the presence of extracellular calcium ion appears necessary.

In contrast to its effect on neurotransmitter-stimulated cyclic AMP accumulation, baclofen inhibits forskolin-stimulated cyclic nucleotide accumulation in cerebral cortical slices (Figure 2). Therefore, in the same tissue preparation, baclofen may either enhance or inhibit cyclic AMP accumulation, depending upon the agent used to stimulate production of the second messenger. Interestingly, like GABA_B sites, activation of α_2 -adrenergic

receptors causes inhibition of adenylate cyclase in brain membranes but augments cyclic AMP production in brain slices. Therefore, it is possible that functionally distinct GABA_B receptors are present in brain, just as the existence of subpopulations of α_2 -adrenergic receptors has been proposed.

Recently, GABA and baclofen have been reported to inhibit histamine (H₁) and serotonin (5-HT₂) receptor-mediated inositol phosphate accumulation in slices of rat and mouse cerebral cortical slices, respectively (Table 2). Whether this represents a direct effect, or is mediated indirectly as a consequence of changes in cyclic AMP production, is unknown. Nonetheless, these findings provide further evidence supporting a neuromodulatory role for GABA acting through GABA_B receptors and should be considered when evaluating the possible existence of multiple GABA_B receptor subtypes.

Electrophysiological studies of GABA_B receptors support the existence of multiple GABA_B receptor subtypes (Table 2). In cultured embryonic dorsal root ganglion cells, GABA and baclofen elicit a bicuculline-insensitive reduction in the duration of the calcium-dependent action potential by decreasing calcium current. A similar mechanism has been proposed to account for the ability of GABA and baclofen to reduce neurotransmitter release from primary afferent terminals.

When applied to rat hippocampal pyramidal cells, baclofen elicits a postsynaptic hyperpolarizing response due to an increase in potassium conductance. GABA_B receptors located presynaptically in the hippocampus and cerebral cortex also inhibit synaptic transmission. Therefore, it appears that

GABA_B receptors are located both pre- and post-synaptically, and influence both Ca⁺⁺ and K⁺ ion conductances.

These data indicate that activation of GABA_B receptors causes a variety of cellular responses. It remains unclear, however, whether these responses are mediated by a single GABA_B receptor entity that has different kinetic properties, is differently localized and coupled to distinct effector mechanisms, or whether there exists pharmacologically and functionally distinct GABA_B receptor subtypes. One way to address this issue is through the uses of receptor-selective antagonists. For example, the discovery that bicuculline selectively blocks GABA-mediated responses was vital in establishing a neurotransmitter role for this amino acid. More recently, in an effort to discover selective GABA_B receptor antagonists, the corresponding phosphonic (phaclofen) and sulfonic acid (2-OH saclofen) derivatives of baclofen were synthesized (Figure 3). Phaclofen antagonizes GABA_B receptor-mediated depression of the ileal twitch response, as well as baclofen-induced reduction of interneuron discharge in spinal cord. In brain, phaclofen selectively inhibits K⁺-dependent hyperpolarization elicited by baclofen in thalamic, hippocampal, and dorsolateral septal neurons. Likewise, 2-OH saclofen antagonizes GABA- and baclofen-induced depression of electrically-stimulated smooth muscle contractions. Although the utility of these compounds is limited by their lack of potency (pA₂ = 4-5), these studies have contributed to establishing a physiological role for GABA_B receptors.

Using 2-OH saclofen, efforts were made to determine whether the receptors mediating the inhibitory response to baclofen on adenylate cyclase differed from those responsible for augmenting second messenger accumulation in brain tissue.

The results of these experiments revealed that 2-OH saclofen reduces the potency of baclofen to enhance isoproterenol-stimulated cyclic AMP accumulation, and blocks the adenylate cyclase inhibitory response to baclofen (Figure 5). This finding suggests that 2-OH saclofen is incapable of differentiating between these two receptor responses.

Evidence for the existence of pharmacologically distinct GABA_B receptor subtypes was provided by the finding that, like baclofen, 3-aminopropylphosphonic acid (3-APPA) reduced forskolin-stimulated cyclic AMP accumulation, but unlike baclofen, does not enhance catecholamine-stimulated cyclic AMP production (Table 3). The inhibition of the forskolin response by 3-APPA was not additive with baclofen, consistent with the notion that the two amino acid receptor agonists act at the same site. While these findings suggested that 3-APPA is a selective GABA_B receptor agonist, additional studies revealed that it antagonizes the effect of baclofen on catecholamine-stimulated cyclic AMP accumulation (Figure 6). Interestingly, 3-APPA has been reported to be a partial agonist in the gut as well as in the central nervous system, whereas it behaves as an antagonist in guinea pig airway. These findings suggest that in addition to being functionally distinct, the GABA_B receptors associated with the forskolin and catecholamine effects on cyclic AMP production are pharmacologically discrete. In addition, it appears that GABA_B receptors located in the central nervous system may differ from those located in the periphery.

Various GABA derivatives have been tested for their ability to interact with cyclic AMP-generating systems in rat brain slices (Figure 7). For example, both 2-butyl and 2-decyl GABA inhibit the baclofen augmenting response but,

unlike 2-OH saclofen, 2-decyl GABA has no effect on forskolin-stimulated cyclic AMP accumulation (Figure 8).

While these results appear to support the existence of multiple GABA_B receptor subtypes, it is troubling that the concentrations of these compounds required to activate or inhibit GABA_B sites are quite high. Thus, in the cyclic AMP studies, in general it was necessary to examine concentrations of test compound above 100 μ M, enhancing the possibility of observing a non-specific effect. For this reason alternative approaches have been used to discriminate between GABA_B receptor subtypes. For example, inasmuch as IAP blocks baclofen-mediated inhibition of adenylate cyclase in brain membranes, attempts were made to determine if toxin treatment also affects the baclofen augmenting response. Indeed, both intracerebroventricular and intrahippocampal injections of IAP prevent baclofen from inhibiting forskolin-stimulated cyclic AMP accumulation. However, whereas IAP treatment reduces the augmenting response in cortical slices, it fails to alter the augmenting response in hippocampal tissue. While this result may be due to the differences in tissue preparation or other experimental variables, it remains possible that the receptor mechanisms differ in these two brain regions. In any event, the results fail to prove whether IAP-sensitive G proteins mediate both the augmenting and the inhibitory responses to baclofen.

Several approaches have been taken to determine whether the pre- and postsynaptic events elicited by baclofen in CA1 hippocampal pyramidal cells are mediated by the same receptor. Phaclofen blocks postsynaptic events, including baclofen-induced hyperpolarizing response and the slow inhibitory postsynaptic

potential seen following CA1 afferent stimulation. In contrast, suppression of the presynaptic excitatory postsynaptic potential elicited by afferent stimulation is phaclofen-insensitive. Likewise, IAP treatment reduces the postsynaptic, but not the presynaptic, response to baclofen. These data also support the existence of distinct GABA_B receptors in terms of their pharmacological selectivity and effector coupling mechanisms.

SUMMARY AND CONCLUSIONS

Much has been learned about the pharmacological, biochemical and physiological properties of GABA_B receptors. These studies have demonstrated that GABA plays a neuromodulatory role through its interaction with GABA_B receptors, and suggest that the GABA_B receptor system is complex. The available evidence seems to favor the existence of pharmacologically and functionally distinct GABA_B receptor subpopulations. Thus, receptor binding experiments revealed that [³H]GABA binds to both low and high affinity GABA_B sites, biochemical analyses indicate the involvement of GABA_B receptors in a variety of second messenger pathways, and electrophysiological studies have shown that GABA_B receptors are responsible for mediating multiple ion channels at both pre- and postsynaptic sites. The present challenge is to determine whether these observations are interrelated, and how each contributes to the physiological role of GABA_B receptors. To address these issues, it will be necessary to develop more potent and selective GABA_B receptor agonists and antagonists. Recently, 3-aminopropylphosphinic acid has been shown to possess GABA_B agonist-like activity in guinea pig ileum and rat anococcygeus smooth muscle preparations with a potency 5-7 times greater than baclofen. An antagonist with equal or greater

affinity would be a valuable pharmacological tool. Indeed, based on present knowledge, it would appear that modification of GABA_A receptor function may prove useful in the treatment of a variety of disorders, including depression, schizophrenia, anxiety, genitourinary dysfunction, and bronchial asthma. Moreover, because GABA seems to act principally as a neuromodulator at GABA_A receptors, receptor agonists and antagonists for this site might prove to be less toxic than existing agents.

TABLE 1

Central and Peripheral Effects of Baclofen

CENTRALLY-MEDIATED ACTIONS

- antinociceptive
- antispastic
- sedative

EFFECTS ON ORGAN SYSTEMS

- reduces intestinal motility in vitro
- inhibits airway smooth muscle contractility in vitro
- blocks vagally-mediated bronchoconstriction in vivo
- reduces uterine and bladder contractions in vitro

TABLE 2

Evidence for Multiple GABA_B Receptor Systems

BINDING

- [³H]GABA and [³H]baclofen label both low and high affinity GABA_B binding sites

BIOCHEMICAL

- inhibits adenylate cyclase activity in brain membranes
- reduces forskolin-stimulated cyclic AMP accumulation in brain slices
- augments neurotransmitter-stimulated cyclic AMP accumulation in brain slices
- attenuates neurotransmitter-stimulated inositol phosphate formation in brain slices

ELECTROPHYSIOLOGICAL

- hyperpolarization resulting from increased K⁺ conductance
- reduces voltage-sensitive Ca⁺⁺ conductance

TABLE 3

Effect of 3-APPA on Iso- and Forskolin-Stimulated cAMP Production

Figure 1: Effect of (+)(-)-Baclofen on NE-Stimulated cAMP Accumulation

CENTRAL AND PERIPHERAL EFFECTS OF BACLOFEN

CENTRALLY-MEDIATED ACTIONS

- antinociceptive
- antispastic
- sedative

EFFECTS ON ORGAN SYSTEMS

- reduces intestinal motility in vitro
- inhibits airway smooth muscle contractility in vitro
- blocks vagally-mediated bronchoconstriction in vivo
- reduces uterine and bladder contractions in vitro

EVIDENCE FOR MULTIPLE GABA_B RECEPTOR SYSTEMS

BINDING

- [³H] GABA and [³H] baclofen label both low and high affinity GABA_B binding sites

BIOCHEMICAL

- inhibits adenylate cyclase activity in brain membranes
- reduces forskolin-stimulated cyclic AMP accumulation in brain slices
- augments neurotransmitter-stimulated cyclic AMP accumulation in brain slices
- attenuates neurotransmitter-stimulated inositol phosphate formation in brain slices

ELECTROPHYSIOLOGICAL

- hyperpolarization resulting from increased K⁺ conductance
- reduces voltage-sensitive Ca⁺⁺ conductance

TABLE 3

Effect of Baclofen and 3-Aminopropylphosphonic Acid on Isoproterenol- and Forskolin-Stimulated Cyclic AMP Accumulation

Treatment	Cyclic AMP Accumulation (% Conversion)		
	Control	+ Baclofen	+ 3-APPA
Untreated	0.28	0.49	0.25
Isoproterenol	0.74	1.62	0.71
Forskolin	4.17	2.67	3.02

Figure 1







Figure 2

BACLOFEN INHIBITION OF FK-STIMULATED CAMP ACCUMULATION





Baclofen




2-OH Saclofen




GABA



3-APPA



2-Butyl GABA



2-Decyl GABA

Figure 4

EFFECT OF 2-OH SACL OFEN ON POTENTIATION




Figure 5.

EFFECT OF 2-OH SACL OFEN ON INHIBITION




Figure 6.

EFFECT OF 3-APPA ON POTENTIATION




Figure 7

EFFECT OF GABA DERIVATIVES ON POTENTIATION




Figure 8.

EFFECT OF 2-DECYL GABA ON INHIBITION

